Strategic considerations on developing a CHIKV vaccine and ensuring equitable access for countries in need

Area of Science:

• Virology
• Epidemiology
• Vaccinology

Background:

• Chikungunya virus (CHIKV) is a mosquito-borne arbovirus causing significant morbidity and mortality globally.
• CHIKV infection results in substantial disability-adjusted life years (DALYs) lost, estimated at 106,089 globally.
• CHIKV is recognized as a priority pathogen by CEPI and an emerging infectious disease (EID) by WHO, highlighting the urgent need for intervention.

Purpose of the Study:

• To summarize the strategic efforts and considerations of the Coalition for Epidemics Preparedness Innovations (CEPI) in developing a Chikungunya vaccine.
• To discuss strategies for ensuring equitable access to a potential CHIKV vaccine in endemic countries.

Main Methods:

• This perspective article reviews existing literature and CEPI's strategic documents.
• Analysis of global health priorities and vaccine development landscapes.
• Examination of equitable access frameworks for emerging infectious diseases.

Main Results:

• Significant progress has been achieved in CHIKV vaccine development.
• CEPI's strategic approach focuses on accelerating vaccine candidates and addressing global health needs.
• Equitable access remains a critical consideration for global health security.

Conclusions:

• Developing a safe and effective CHIKV vaccine is a global health priority.
• Strategic partnerships and equitable access plans are crucial for mitigating the impact of Chikungunya.
• Continued investment and collaboration are essential for controlling CHIKV outbreaks.